Episode 73
Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, senior director, preclinical research, and Joshua Myers, director of clinical operations, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.”
Join our endocrine community and become a member! Only members receive access to a variety of member benefits that will enhance your career. If your membership has lapsed, rejoin today so that you can continue to receive your membership benefits.
Our top-ranked peer-reviewed journals are among the first to publish major developments and discovery milestones.
